Serial 98740260
Live / Applied — First extension granted (statement of use) (as of 05 Jan 2026)
What this means for you
Not registered yet, but its 09 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98740260
- Mark type
- Design / logo
- Filed
- 09 Sept 2024
- Published for opposition
- 17 Jun 2025
- Attorney of record
- Tiffany D. Gehrke
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, small-molecule drugs for the treatment of cancer, metabolic disorders, and endocrine disorders; Pharmaceutical and biologic preparations for use in the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of diabetes and obesity-related diseases and disorders; Peptides for pharmaceutical purposes, namely, for the treatment of cancer, metabolic disorders, and endocrine disorders
- Class 042 — Scientific and technological services: Pharmaceutical and biologic drug development services, namely, development of small-molecule drugs for use in humans; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of diabetes and obesity-related diseases and disorders; Research and development services in the field of pharmaceutical and biologic preparations; Research and development services in the field of oncology-related diseases and disorders; Research and development services in the field of metabolic-related diseases and disorders; Research and development services in the field of endocrine-related diseases and disorders; Research and development services in the fields of diabetes and obesity-related diseases and disorders; Research and development services in the field of peptide pharmaceutical preparations; Providing medical and scientific research information in the field of small-molecule drugs; Providing medical and scientific research information in the field of clinical trials and post-market trials; Providing medical and scientific research information in the field of oncology, metabolic, endocrine, diabetes, and obesity-related diseases and disorders
Owner
- Terns Pharmaceuticals, Inc., Foster City, CA, US
- Terns Pharmaceuticals, Inc., Foster City, CA, US
Prosecution history
- 06 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Jan 2026 — SOU EXTENSION 1 GRANTED
- 05 Jan 2026 — SOU EXTENSION 1 FILED
- 05 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Jun 2025 — PUBLISHED FOR OPPOSITION
- 11 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 03 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 03 Apr 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 31 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 31 Mar 2025 — NON-FINAL ACTION E-MAILED
- 31 Mar 2025 — NON-FINAL ACTION WRITTEN